Sumitomo Pharma Co., Ltd. DNPUF
10.50 USD -1.41 (-11.84%)
At closeOct 30, 2026, 4:00 PM EDT
10.50 Day range 10.50
8.41 52-week range 19.20
- YTD
- -26.88%
- 1 year
- -4.46%
- Market cap
- 4.71B
- EPS (ttm)
- 0.67
- P/E ratio
- 15.67
- YTD return
- -26.88%
- 1-year return
- -4.46%
- Volume
- 118
- Avg volume
- 56
- Open
- 10.50
- Previous close
- 11.91
- Day's range
- 10.50 – 10.50
- 52-week range
- 8.41 – 19.20
- Earnings date
- Nov 4, 2026
1M +2.12 (+21.65%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.1248.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.1248 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.1176 | 0.2399 | +0.12 | +104.00% |
| May 13, 2026 | Mar 31, 2026 | -0.09599 | -0.01285 | +0.08 | +86.61% |
| Jan 30, 2026 | Dec 31, 2025 | -0.00555 | 0.1416 | +0.15 | +2,651.35% |
| Oct 31, 2025 | Sep 30, 2025 | 0.534 | 1.49 | +0.96 | +179.03% |
| Jul 31, 2025 | Jun 30, 2025 | 0.1368 | 0.1957 | +0.06 | +43.06% |
News
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia 
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript 
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Your note
Sign in to keep a note on DNPUF — it syncs with the Stock Master app.